DIA MASC 2025

Medical Affairs 2.0: GenAI as the Catalyst for Change in Writing, MedComms, and Field Strategy

Digital and AI were hot topics underpinning many of the conversations at the DIA’s Medical Affairs and Scientific Communications (DIA MASC) forum I attended in March 2025, along with a focus on how we can utilize these tools to achieve impactful, engaging, and scientifically accurate communications that resonate with healthcare providers (HCPs) and patients. Along…...
Read More

Top Stories

Biopharma 2025 Trends

Biopharma Trends 2025: 3 Things to Know Right Now

The global business climate is ever-evolving, and 2025 looks...
AI in Medical Affairs & Medical Communications

Science, AI, and Human Ingenuity Converge to

Today, we're witnessing an unprecedented convergence of...

The Paradigm Shift from Traditional Scientific

In the rapidly evolving biopharma landscape, the approach to...

MedTech Summit 2021: Understanding Post Market Clinical Follow Up (PCMF)

An ideal PMCF plan, with reference to MDCG 2020-7, presents the general and specific methods...

Bringing New Devices to Market under the EU MDR

With the MDR coming into effect, the manufacturers should plan and construct their strategy to...
Clinical Trial Pain Points

Pharma, Physician, and Patient Pain Points Regarding Clinical Trials

Pharma, physicians, and patients consistently face challenges related to clinical trials. Here's a quick look...
FINAL Clinical Trial Summaries Blog-Banner-810x540

Clinical Trial Summaries – What Are They and Why Do They Matter for Pharma?

A majority of patients feel lay summaries for clinical trials are very important and won’t...
Building public trust in pharma

3 Factors That Will Help Pharma Build Public Trust

Pharma must engage with patients at all levels to build public trust...
Vaccine

Role of Scientific Communication and Medical Professionals in Combating Vaccine Hesitancy

Read an insightful discussion from the latest ISMPP conference on how science communication and medical...

Learn more ABOUT our company.